ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SXTPW 60 Degrees Pharmaceuticals Inc

0.0241
0.00 (0.00%)
Feb 26 2025 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.021
Ask Price 0.035
News -
Company Name Stock Ticker Symbol Market Type
60 Degrees Pharmaceuticals Inc SXTPW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.0241 16:30:00
Open Price Low Price High Price Close Price Prev Close
0.0241 0.0241
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0  0.0241 USD

60 Degrees Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
139.78k 5.80M - 254k -3.77M -0.65 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split GlobeNewswire Inc. • Thu Feb 20, 2025 10:36 AM (6 days ago)
Form D - Notice of Exempt Offering of Securities Edgar (US Regulatory) • Tue Feb 11, 2025 5:23 PM (2 weeks ago)
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® GlobeNewswire Inc. • Tue Feb 11, 2025 12:59 PM (2 weeks ago)
Form 8-K - Current report Edgar (US Regulatory) • Thu Feb 06, 2025 4:41 PM (3 weeks ago)
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. • Thu Feb 06, 2025 2:07 PM (3 weeks ago)
Form 424B5 - Prospectus [Rule 424(b)(5)] Edgar (US Regulatory) • Thu Feb 06, 2025 10:04 AM (3 weeks ago)
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. • Wed Feb 05, 2025 9:22 AM (3 weeks ago)
Form 8-K - Current report Edgar (US Regulatory) • Thu Jan 30, 2025 5:30 PM (4 weeks ago)
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. • Thu Jan 30, 2025 2:20 PM (4 weeks ago)
Form 424B5 - Prospectus [Rule 424(b)(5)] Edgar (US Regulatory) • Thu Jan 30, 2025 8:28 AM (4 weeks ago)
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. • Wed Jan 29, 2025 8:00 AM (4 weeks ago)
Form 8-K - Current report Edgar (US Regulatory) • Tue Jan 28, 2025 4:05 PM (4 weeks ago)

Loading Messages....


See More Message Board Posts

SXTPW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.

NASDAQ:SXTPW -

What is the current 60 Degrees Pharmaceuticals Inc share price?
The current share price of 60 Degrees Pharmaceuticals Inc is $ 0.0241
How many 60 Degrees Pharmaceuticals Inc shares are in issue?
60 Degrees Pharmaceuticals Inc has 5,800,000 shares in issue
What is the market cap of 60 Degrees Pharmaceuticals Inc?
The market capitalisation of 60 Degrees Pharmaceuticals Inc is USD 139.78k
What is the 1 year trading range for 60 Degrees Pharmaceuticals Inc share price?
60 Degrees Pharmaceuticals Inc has traded in the range of $ 0.00 to $ 0.00 during the past year
What is the PE ratio of 60 Degrees Pharmaceuticals Inc?
The price to earnings ratio of 60 Degrees Pharmaceuticals Inc is -3.11
What is the cash to sales ratio of 60 Degrees Pharmaceuticals Inc?
The cash to sales ratio of 60 Degrees Pharmaceuticals Inc is 46.12
What is the reporting currency for 60 Degrees Pharmaceuticals Inc?
60 Degrees Pharmaceuticals Inc reports financial results in USD
What is the latest annual turnover for 60 Degrees Pharmaceuticals Inc?
The latest annual turnover of 60 Degrees Pharmaceuticals Inc is USD 254k
What is the latest annual profit for 60 Degrees Pharmaceuticals Inc?
The latest annual profit of 60 Degrees Pharmaceuticals Inc is USD -3.77M
What is the registered address of 60 Degrees Pharmaceuticals Inc?
The registered address for 60 Degrees Pharmaceuticals Inc is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the 60 Degrees Pharmaceuticals Inc website address?
The website address for 60 Degrees Pharmaceuticals Inc is 60degreespharma.com
Which industry sector does 60 Degrees Pharmaceuticals Inc operate in?
60 Degrees Pharmaceuticals Inc operates in the PHARMACEUTICAL PREPARATIONS sector